Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.

Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials.

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Dr. Walker, Dr. Carlson, Dr. Carter, Dr. Covens, Dr. Tanner, Dr. Amer, Dr. Hayes, Dr. Lopez-Acevedo, Dr. Davidson, Dr. Schaverien, Dr. Ghamande, Dr. Cheville, Dr. Yost, Dr. Schmitz, Dr.Ford and Michael Bernas report no conflicts of interest. Dr. Russo and Dr. McCaskill-Steven report grants from government to support this workshop. Dr. Ward reports personal fees from Impedimed Inc., outside the submitted work. Dr. Ridner reports grants from Impedimed, during the conduct of the study. Dr. Taghian reports consultancy with PureTech Health, previous consultancy with VisionRT, grants from Adele McKinnon Research Fund for Breast Cancer-Related Lymphedema, grants from The Heinz Family Foundation, grants from The Olayan-Xefos Family Fund for Breast Cancer Research, grants from National Cancer Institute Award Number P50CA08393, grants from National Cancer Institute Award Number R01CA139118, non-financial support from Impedimed outside the submitted work. Cheryl. Brunelle is on the Scientific Advisory Board for PureTech Health outside the submitted work. Dr. Davidson reports speaking honorarium from Tesaro outside the submitted work. Dr. Ghamande reports consultancy/speaker with GSK/Tesaro outside the submitted work. Dr. Enserro reports grants from NRG Oncology NCORP, grants from NRG Oncology SDMC during the conduct of the study, outside the submitted work. Dr. Pugh reports other from Pfizer, other from Millennium outside the submitted work. Dr. Paskett reports grants from Merck Foundation, grants from Pfizer, other from Pfizer, grants from Komen Columbus Foundation, grants from Ohio Department of Health, grants from Breast Cancer Research Foundtaion, grants from NIH, other from FoxConn, grants from Social Impact Fund, grants from Komen Foundation, grants from PICORI outside the submitted work.